The introduction of tumor necrosis factor immunobiological blocking agents (anti-TNF) has brought great advances in the treatment of autoimmune diseases. Currently, there are five anti-TNF drugs available (infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol), which can be used in the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, 
multiple sclerosis, optic neuritis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. 1 We 
